Quarterly report (Form 10-Q)
Church & Dwight 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
meet our capital expenditure program costs, which are expected to be approximately $125.0 in 2026 including manufacturing capacity investments for THERABREATH® and Sterimar and an enterprise resource planning (ERP) project.